VAERS Explorer
Back to explore

Report #2881581

Received Jan 12, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
0.5 yrs
State
MO
Recovered
Unknown
Vaccinated
Jan 7, 2026
Onset
Jan 7, 2026
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
FLU3INFLUENZA (SEASONAL) (FLULAVAL)GLAXOSMITHKLINE BIOLOGICALS24F2AJ—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

received the 1st dose of Flulaval, then instead of the 4 weeks waiting interval, the patient received 2nd dose early; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 6-month-old male patient who received Flu Seasonal TIV Quebec (FluLaval 2025-2026 season) (batch number 4F2AJ, expiry date 26-JUN-2026) for prophylaxis. Concomitant products included Influenza vaccine inact split 3v (Flulaval). On 07-JAN-2026, the patient received the 2nd dose of FluLaval 2025-2026 season. On 07-JAN-2026, an unknown time after receiving FluLaval 2025-2026 season, the patient experienced drug dose administration interval too short (Verbatim: received the 1st dose of Flulaval, then instead of the 4 weeks waiting interval, the patient received 2nd dose early). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.